Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis

Rheumatology

Volumn 42, Issue 6, 2003, Pages 743-749

  Ringe, J D ^a   Dorst, A ^a   Faber, H ^a   Ibach, K ^a   Preuss, J ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Alfacalcidol; Bisphosphonate; Bone density; Corticosteroid induced osteoporosis; Facture reduction; Ibandronate

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM DERIVATIVE; CORTICOSTEROID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; 1-HYDROXYCHOLECALCIFEROL; GLUCOCORTICOID; HYDROXYCOLECALCIFEROL;

ADULT; AGED; ARTICLE; BACKACHE; BOLUS INJECTION; BONE MINERAL; CALCANEUS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; FEMALE; FEMUR NECK; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; INTESTINE ULCER; KIDNEY DYSFUNCTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT PLANNING; VERTEBRA FRACTURE; BONE DENSITY; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; LUMBAR VERTEBRA; MIDDLE AGED; OSTEOPOROSIS; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; SPINE FRACTURE;

AGED; BACK PAIN; BONE DENSITY; CALCANEUS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEMUR NECK; GLUCOCORTICOIDS; HUMANS; HYDROXYCHOLECALCIFEROLS; INJECTIONS, INTRAVENOUS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSPECTIVE STUDIES; SPINAL FRACTURES;

EID: 0037926696     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg205     Document Type: Article

References (57)

1. Hougardy DM, Peterson GM, Bleasel MD, Randall CT. Is enough attention being given to the adverse effects of corticosteroid therapy? J Clin Pharm Ther 2000;25:22-34.
2. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. Br Med J 1996;313:34-6.
3. Adachi JD. Corticosteroid-induced osteoporosis. Am J Med Sci 1997;313:4-9.
4. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983; 309:26-8.
5. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995;54:49-52.
6. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis. pathogenesis and management. Ann Intern Med 1990; 112:352-64.
7. Reid IR. Glucocorticoid osteoporosis-mechanisms and management. Eur J Endocrinol 1997;137:209-17.
8. Sambrook PN, Birmingham J, Kempler S. Corticosteroid effects on proximal femur bone loss. J Bone Miner Res 1990;5:1211-6.
9. Verstraeten A, Dequeker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 1986;45:852-7.
10. Ringe JD. Active vitamin D metabolites in glucocorticoid-induced osteoporosis. Calcif Tissue Int 1997;60:124-7.
11. Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 1991;46:803-6.
12. Adachi JD, Bensen WG, Brown J et al. Intermittent etidronate therapy to prevent CIO. N Engl J Med 1997; 337:382-7.
13. Cohen S, Levy RM, Keller M et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-18.
14. Reid DM, Hughes RA, Laan RF et al. Efficacy and safety of daily risedronate in the treatment of CIO in men and women: a randomized trial. European CIO Treatment Study. J Bone Miner Res 2000;15:1006-13.
15. Roux C, Oriente P, Laan R et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 1998;83:1128-33.
16. Saag KG, Emkey R, Schnitzer TJ et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-9.
17. American College of Rheumatology Ad HoC Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44:1496-503.
18. de Groen PC, Lubbe DF, Hirsch LJ et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;35:1016-21.
19. Lufkin EG, Argueta R, Whitaker MD. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporosis Int 1994;4:320-22.
20. Sharpe M, Noble S, Spencer CM. Alendronate. An update of its use in osteoporosis. Drugs 2001;61:999-1039.
21. Adami S, Zamberlan N. Adverse effects of bisphosphonates: a comparative review. Drug Safety 1996;14:158-70.
22. Adami S. Ibandronate. Drugs 1999;57:109.
23. Roldán EJA, Negri AL, Gador SA. Short-term compliance to daily alendronate treatment in 1877 patients with osteoporosis. The ECMO study. J Bone Miner Res 2000; 15(Suppl. 1):SU411.
24. Lombas C, Hakim C, Zanchetta JR. Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 2000;15(Suppl. 1):M406.
25. Colley CA, Lucas LM. Polypharmacy: the cure becomes the disease. J Gen Intern Med 1993;8:278-83.
26. Stewart RB, Cooper JW. Polypharmacy in the aged. Practical solutions. Drugs Aging 1994;4:449-61.
27. Tashkin DP. Multiple dose regimens. Impact on compliance. Chest 1995;107:176S-182S.
28. Gatley MS. To be taken as directed. J R Coll Gen Pract 1968;16:39-44.
29. James PN, Anderson JB, Prior JG, White JP, Henry JA, Cochrane GM. Patterns of drug taking in patients with chronic airflow obstruction. Postgrad Med J 1985; 61:7-10.
30. Latiolais CJ, Berry CC. Misuse of prescription medications by outpatients. Drug Intelligence Clin Pharm 1969; 3:271-77.
31. Bauss F, Kling L, Sponer G. Comparison of continuous and cyclical administration of ibandronate on bone mass in ovariectomized rats. J Bone Miner Res 1996;11(Suppl. 1): S336.
32. Burckhardt P. Ibandronate in oncology. Cancer 1997; 80(Suppl. 8):1696-8.
33. Coleman RE, Purohit OP, Black C et al. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 1999;10:311-6.
34. Fleisch H. The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by calcium kinetics in the intact rat. Osteoporosis Int 1996;6:166-70.
35. Lalla S, Hothorn LA, Haag N, Bader R, Bauss F. Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporosis Int 1998;8:97-103.
36. Monier-Faugere MC, Friedler RM, Bauss F, Malluche HH. A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res 1993;8:1345-55.
37. Monier-Faugere MC, Geng Z, Paschalis EP et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res 1999;14:1768-78.
38. Pecherstorfer M, Herrmann Z, Body JJ et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996;14:268-76.
39. Ravn P, Clemmesen B, Riis BJ, Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996;19:527-33.
40. Riis BJ, Ise J, von Stein T, Bagger Y, Christiansen C. Ibandronate: a comparison of oral daily vs intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001;16:1871-8.
41. Ralston SH, Thiebaud D, Herrmann Z et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 1997;75:295-300.
42. Smith SY, Recker R, Hannan M, Bauss F. Effects of ibandronate treatment on bone mass, architecture and strength in the ovariectomized cynomolgus monkey [Abstract SA370]. J Bone Miner Res 1999;14(Suppl. 1):S402.
43. Thiébaud D, Burckhardt P, Kriegbaum H et al. Three monthly i.v. injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997; 103:298-307.
44. Cummings SR, Black DM, Nevitt MC et al. Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. J Am Med Assoc 1990;263:665-8.
45. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of BMD predict occurrence of osteoporotic fractures. Br Med J 1996;312:1254-9.
46. Adachi JD, Roux C, Pitt PI et al. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. J Rheumatol 2000;27:2424-31.
47. Gallacher SJ, Fenner JA, Anderson K et al. I.v. pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. Thorax 1992;47:932-6.
48. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000; 11: S2-17.
49. Garnero P, Hausherr E, Chapuy MC et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996; 11:1531-8.
50. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000;15:1526-36.
51. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 1999;14:1614-21.
52. Hansen MA, Overgaard K, Riis BJ, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. Br Med J 1991;303:961-4.
53. Ross PD, Kress BC, Parson RE et al. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 2000; 11:76-82.
54. Uebelhart D, Schlemmer A, Johansen JS et al. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 1991;72:367-73.
55. van Daele PL, Seibel MJ, Burger H et al. Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study. Br Med J 1996;312:482-3.
56. Papapoulos SE. Bisphosphonates in the treatment of osteoporosis. Principles and efficacy. Ann Med Interne 2000;151:504-10.
57. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-26.